Zentalis Grants Options for 136,000 Shares
Four newly hired employees received non-qualified stock options at $1.85 per share under the company's 2022 inducement plan.
Updated on Nov. 2, 2026 in Stock Picks
Zentalis Pharmaceuticals granted non-qualified stock options covering 136,000 shares to four newly hired employees on November 2, 2026. The options carry an exercise price of $1.85 per share, equal to the closing price on The Nasdaq Global Market on the grant date.
Why it matters
The grants were made as inducement material for each individual entering employment with Zentalis, under a plan limited to people not previously employed by the company or returning after a bona fide break. Such awards are a common way companies recruit talent while tying compensation to future share price performance.
The grant covers 136,000 shares at an exercise price of $1.85, set at the closing price on The Nasdaq Global Market on November 2, 2026. The filing does not disclose the stock's price movement after the grant or the company's total outstanding option pool.
The players
Zentalis Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company headquartered in San Diego and listed on the Nasdaq Global Market, focused on developing cancer therapies.
The details
The options have a 10-year term and vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the following three years. Vesting depends on each employee's continued service to Zentalis on each vesting date.
Timeline
November 2, 2026: Compensation Committee of Zentalis' Board of Directors grants the options.
First anniversary of vesting commencement date: 25% of the options vest.
Over the following three years: remaining 75% of options vest in equal monthly installments.
Ten years from grant: options expire at the end of their term.
Market Dynamics
The grant follows the exemption in Nasdaq Listing Rule 5635(c)(4), which lets listed companies issue inducement awards to new hires without a shareholder vote. Such awards are a standard recruitment tool across biotech firms that compete for scarce specialized talent.
For shareholders, the grants add dilution only if the options are exercised, and the vesting schedule means no shares become available before the first anniversary. Investors tracking Zentalis can check the company's filings for the total outstanding option count after these grants.
The takeaway
Equity inducement grants are a common recruiting tool, and their long vesting periods tie employee rewards to sustained service. Investors often weigh such grants against a company's overall dilution profile over time.
Further reading
For more on how equity grants like this factor into company valuations, see Stock Picks coverage.
Source note: This article includes information reported by The Manila times.
